Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new hypertension ...

Novo Nordisk, manufacturer of the weight loss jab Wegovy, has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations (Alamy/PA ...

Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought ...

Though in different sectors, these stocks all share a wide moat and unrivaled scale.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best drug stocks to buy now. Is China the Next Big Thing in the Pharmaceutical Industry?